Sienna's long-serving CEO steps down
Sienna Cancer Diagnostics has announced the resignation of CEO Dr Kerry Hegarty after 10 years at the helm.
The company has commenced a global search for a replacement, and Hegarty plans to stay on in a support capacity until a new chief is found.
Sienna Chairman Dr Geoff Cumming said Hegarty’s resignation serves as part of a long-term strategic transformation plan for the company.
“Over the past 12 months, Kerry and the board have been assessing the needs of the company as it embarks on its next chapter, including leadership and management needs for the next 2-3 years,” he said.
“As part of this process, the board and Kerry have agreed that now is an opportune time to attract a new and outstanding CEO to a transformed Sienna to lead the company into a new phase in its history, and allow Kerry to pursue other opportunities after many years of service.”
The move comes the same month Sienna secured its first revenue-generating deal for its telomerase detection technology based on Anti-hTERT antibody SCD-A7.
The company also recently completed a $2.1 million capital raising to help fund SCD-A7 development.
Hormone therapy shifts body proteins to match gender identity
Researchers have discovered that gender-affirming hormone therapy can alter body proteins to...
Targeting 'molecular bodyguards' weakens prostate cancer cells
Research reveals that two enzymes — PDIA1 and PDIA5 — act as 'molecular...
Females found to carry a higher genetic risk of depression
An international team of scientists has discovered about twice as many genetic 'flags'...
